AbbVie and Samsung Bioepis resolve Humira litigation

09-04-2018

AbbVie and Samsung Bioepis resolve Humira litigation

miodrag ignjatovic / iStockphoto.com

AbbVie has secured another settlement relating to litigation over Humira (adalimumab), a drug used to treat multiple types of arthritis as well as psoriasis.


AbbVie, Samsung Bioepis, Humira, patent infringement, settlement, litigation, biosimilar

LSIPR